| abstract |
A stable c-Met antibody-drug conjugate (c-Met ADC) formulation and use thereof in medicine are described. In particular, the formulation contains c-Met ADC, a buffer, and can also contains at least one stabilizer, and optionally a surfactant. The c-Met ADC formulation of the application can effectively inhibit the aggregation and isomerization of antibodies, and prevent the degradation of an antibody product therein, being a stable injectable pharmaceutical formulation. |